Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

IVVD

Invivyd Inc

May 15 • 11:09AM ET

1.32

+0.16 13.79 %

Healthcare • Biotechnology • USA • Small • NASD

May 14, 7:05 PMInvivyd Q1 2026 results miss estimates as it expands monoclonal antibody pipeline to measles, mumps, rubella, Lyme disease and other pathogens

Peers: VIR NVAX ARCT INO OCGN

| Held by: VTI XBI VXF ITOT PRFZ LABU BBC IBBQ BIB PWS

Index	-	P/E	-	EPS (ttm)	-0.36	Insider Own	20.54%	Shs Outstand	282.80M	Perf Week	-12.00%
Market Cap	373.30M	Forward P/E	-	EPS next Y	-0.41	Insider Trans	-0.30%	Shs Float	224.71M	Perf Month	-22.81%
Enterprise Value	197.78M	PEG	-	EPS next Q	-0.10	Inst Own	85.59%	Short Float	13.02%	Perf Quarter	-15.38%
Income	-77.60M	P/S	6.68	EPS this Y	-31.11%	Inst Trans	28.77%	Short Ratio	10.65	Perf Half Y	-25.42%
Sales	55.87M	P/B	1.84	EPS next Y	-2.98%	ROA	-44.92%	Short Interest	29.26M	Perf YTD	-46.56%
Book/sh	0.72	P/C	2.03	EPS next 5Y	22.26%	ROE	-60.34%	52W High	3.07 -57.00%	Perf Year	87.50%
Cash/sh	0.65	P/FCF	-	EPS past 3/5Y	48.48% 12.29%	ROIC	-36.94%	52W Low	0.48 173.29%	Perf 3Y	-13.73%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	89.57%	Volatility	8.34% 7.26%	Perf 5Y	-
Dividend TTM	-	EV/Sales	3.54	EPS Y/Y TTM	70.13%	Oper. Margin	-146.38%	ATR (14)	0.14	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.46	Sales Y/Y TTM	52.27%	Profit Margin	-138.90%	RSI (14)	42.94	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.47	EPS Q/Q	1.62%	SMA20	-9.47%	Beta	0.66	Target Price	10.00
Payout	-	Debt/Eq	0.04	Sales Q/Q	21.59%	SMA50	-13.33%	Rel Volume	4.77	Prev Close	1.16
Employees	122	LT Debt/Eq	0.03	Earnings	May 14 BMO	SMA200	-20.94%	Avg Volume	2.75M	Price	1.32
IPO	Aug 06, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-77.35% -23.82%	Trades		Volume	3,811,998	Change	13.79%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-22-25	Initiated	BTIG Research	Buy	$10
Nov-25-25	Downgrade	D. Boral Capital	Buy → Hold
Oct-06-25	Initiated	Cantor Fitzgerald	Overweight	$10
Apr-05-24	Upgrade	Guggenheim	Neutral → Buy	$9
Mar-26-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$4 → $10
Dec-19-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$1 → $4
May-01-23	Initiated	H.C. Wainwright	Buy	$5

May-14-26 07:01PM	Invivyd Inc (IVVD) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Investments (GuruFocus.com) -21.09% +13.79%
07:01AM	Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
May-11-26 07:01AM	Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination (GlobeNewswire)
May-07-26 07:01AM	Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026 (GlobeNewswire)
May-05-26 07:01AM	Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.44%
07:01AM	Loading…
Apr-20-26 07:01AM	Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit (GlobeNewswire)
Apr-09-26 07:01AM	Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles (GlobeNewswire) +31.85%
Apr-07-26 07:01AM	Invivyd Launches "Antibodies for Any Body" in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health (GlobeNewswire)
Apr-06-26 07:01AM	Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-30-26 04:05PM	Invivyd Announces Presentation at the World Vaccine Congress Washington (GlobeNewswire) -13.14% +9.24%
Mar-05-26 09:07PM	Invivyd Q4 Earnings Call Highlights (MarketBeat)
04:02PM	Invivyd Inc (IVVD) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
12:36PM	Invivyd, Inc. Q4 2025 Earnings Call Summary (Moby)
07:03AM	Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates (GlobeNewswire)
07:01AM	Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer (GlobeNewswire)
04:10PM	Loading…
Mar-02-26 04:10PM	Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026 (GlobeNewswire) -5.81%
04:01PM	Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-26-26 12:15PM	MannKind (MNKD) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Feb-24-26 07:01AM	New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies (GlobeNewswire)
Feb-17-26 05:10PM	Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +6.45%
Feb-03-26 07:01AM	Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration (GlobeNewswire) +8.05%
Jan-22-26 07:01AM	Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention (GlobeNewswire)
Jan-20-26 07:01AM	Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026 (GlobeNewswire) -8.57%
Jan-14-26 02:13PM	?Invivyd (IVVD) Reports Strong Q4 Growth, Advances COVID Antibody to Phase 3 (Insider Monkey) +11.11%
Jan-08-26 07:01AM	Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights (GlobeNewswire)
Dec-31-25 11:13AM	BTIG Initiates Invivyd (IVVD) Coverage, Cites VYD2311's Superior Market Potential Over Pemgarda (Insider Monkey)
Dec-23-25 07:05AM	Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID (GlobeNewswire)
07:01AM	Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID (GlobeNewswire)
Dec-22-25 09:47AM	Arcellx initiated, Cummins upgraded: Wall Street's top analyst calls (The Fly) +25.22%
Dec-18-25 01:14AM	Invivyd, Inc. (IVVD): Advancing RSV Antibody VBY329 Amid Analyst Downgrade (Insider Monkey)
07:01AM	Loading…
Nov-25-25 07:01AM	Invivyd to Participate at the 8th Annual Evercore Healthcare Conference (GlobeNewswire) -5.42%
Nov-24-25 07:01AM	Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness (GlobeNewswire)
Nov-17-25 10:40PM	Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +20.85% -10.92%
04:01PM	Invivyd Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Nov-06-25 09:15AM	Invivyd, Inc. (IVVD) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:01AM	Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-05-25 07:52AM	Invivyd Inc (IVVD) Q3 2025 Earnings Report Preview: What to Expect (GuruFocus.com) +8.57%
07:40AM	Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-04-25 10:00AM	Viridian Therapeutics, Inc. (VRDN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks) -13.04%
Nov-03-25 04:01PM	Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025 (GlobeNewswire) -8.52%
Oct-28-25 07:01AM	Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID (GlobeNewswire)
Oct-06-25 07:01AM	Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID (GlobeNewswire) +22.41%
Sep-24-25 04:01PM	Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors (GlobeNewswire) +5.17% -6.56%
Sep-23-25 07:25PM	Invivyd, Inc. (IVVD) Secures FDA Path for COVID-19 Antibody Approval (Insider Monkey)
Sep-17-25 07:01AM	Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer (GlobeNewswire) -8.73%
Sep-04-25 07:01AM	SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025 (GlobeNewswire)
Aug-27-25 07:01AM	Invivyd to Participate in Upcoming Investor Conferences (GlobeNewswire) -15.44%
Aug-26-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +84.03%
Aug-22-25 12:00PM	Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares (GlobeNewswire)
Aug-20-25 11:58PM	Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +11.00% -16.71%
04:01PM	Invivyd Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Aug-18-25 04:32PM	Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG ("Stratus") (GlobeNewswire) -17.82%
Aug-14-25 06:00PM	Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -11.54%
04:49PM	Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
04:47PM	Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19 (GlobeNewswire)
Aug-12-25 05:40PM	Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Aug-08-25 05:30AM	The Race to Find a Measles Treatment as Infections Surge (The Wall Street Journal) +5.88%
Aug-07-25 06:15PM	Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +5.10%
Aug-06-25 08:20AM	Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates (Zacks)
Jul-23-25 07:01AM	Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome (GlobeNewswire) +5.26%
Jul-21-25 07:05AM	National Comprehensive Cancer Network (NCCN) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population (GlobeNewswire)
Jul-02-25 07:01AM	Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome (GlobeNewswire)
Jun-26-25 07:01AM	Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection (GlobeNewswire) +13.43%
Jun-02-25 03:49AM	COVIDs remaining biotech contenders navigate a dwindling market (Pharma Voice)
May-29-25 02:36PM	H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall (Insider Monkey)
May-27-25 07:01AM	Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus (GlobeNewswire) +20.15%
May-23-25 07:01AM	Invivyd Announces Inclusion of PEMGARDA (pemivibart) in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas (GlobeNewswire)
May-21-25 09:30AM	Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19 (GlobeNewswire) -5.52%
May-16-25 03:08AM	Invivyd Inc (IVVD) Q1 2025 Earnings Call Highlights: Strategic Shifts and Financial Discipline ... (GuruFocus.com) +10.33%
01:57AM	Q1 2025 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents)
May-15-25 08:15AM	Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -15.78%
07:01AM	Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
May-14-25 09:53AM	What To Expect From Invivyd Inc (IVVD) Q1 2025 Earnings (GuruFocus.com)
07:01AM	Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy (GlobeNewswire)
May-13-25 07:01AM	Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference (GlobeNewswire)
May-12-25 07:01AM	Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles (GlobeNewswire) +29.67%
May-08-25 07:01AM	Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025 (GlobeNewswire)
Apr-21-25 09:58AM	What's Going On With Invivyd Stock On Monday? (Benzinga) +10.00%
07:01AM	Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank (GlobeNewswire)
Mar-26-25 04:15PM	Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors (GlobeNewswire) -6.70%
Mar-20-25 09:25AM	Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:01AM	Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Mar-12-25 09:40AM	Are Investors Undervaluing Invivyd, Inc. (IVVD) Right Now? (Zacks)
Mar-05-25 07:05AM	Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1 (GlobeNewswire)
Mar-02-25 11:32AM	Why Invivyd, Inc. (IVVD) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-28-25 12:12PM	Adagio Medical cuts workforce and pauses cryo catheter launch in EU (Medical Device Network) -6.45%
Feb-24-25 07:05AM	FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients (GlobeNewswire) -29.94%
Feb-18-25 10:27AM	Why Invivyd, Inc. (IVVD) Is Soaring This Year So Far (Insider Monkey) -9.32%
Feb-10-25 07:00AM	Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 (GlobeNewswire) -23.04%
Feb-05-25 09:30AM	Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold (GlobeNewswire) +68.80%
Feb-03-25 07:20PM	Why Invivyd Inc (IVVD) Is Skyrocketing So Far In 2025 (Insider Monkey) +196.34% +17.92%
07:00AM	Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population (GlobeNewswire)
06:55AM	Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability (GlobeNewswire)
Jan-27-25 07:01AM	Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA's Gating Request for Completing Its Review of EUA Request for PEMGARDA (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients (GlobeNewswire) -12.85%
Jan-10-25 12:12PM	What's Going On With COVID-19 Antibody Developer Invivyd Stock On Friday? (Benzinga)
07:01AM	Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Dominant SARS-CoV-2 Variant XEC (GlobeNewswire)
Jan-07-25 09:34AM	Why Invivyd, Inc. (IVVD) Is Among the Best Penny Stocks to Invest In According to Media? (Insider Monkey)
Dec-17-24 06:25AM	Adagio Medical announces Todd Usen as new CEO and director (Medical Device Network) +8.77%
Nov-15-24 03:17AM	Q3 2024 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents)
02:11AM	Invivyd Inc (IVVD) Q3 2024 Earnings Call Highlights: Strong Revenue and Strategic Growth Amidst ... (GuruFocus.com)

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in New Haven, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Allen Robert D. III	Chief Scientific Officer	Feb 18 '26	Sale	1.58	19,392	30,597	114,487	Feb 18 08:56 PM
Allen Robert D. III	Chief Scientific Officer	Feb 17 '26	Sale	1.54	18,189	28,004	133,879	Feb 18 08:56 PM
Green Julie	Chief Human Resources Officer	Feb 18 '26	Sale	1.58	20,964	33,077	107,717	Feb 18 08:51 PM
Green Julie	Chief Human Resources Officer	Feb 17 '26	Sale	1.54	19,663	30,273	128,681	Feb 18 08:51 PM
Duke William E.	Chief Financial Officer	Feb 18 '26	Sale	1.58	20,964	33,077	107,717	Feb 18 08:49 PM
Duke William E.	Chief Financial Officer	Feb 17 '26	Sale	1.54	19,663	30,273	128,681	Feb 18 08:49 PM
Lee Timothy Edward	Chief Commercial Officer	Feb 18 '26	Sale	1.58	20,964	33,077	117,717	Feb 18 08:47 PM
Lee Timothy Edward	Chief Commercial Officer	Feb 17 '26	Sale	1.54	19,663	30,273	138,681	Feb 18 08:47 PM
Andersen Jill	Chief Legal Officer, Secretary	Feb 18 '26	Sale	1.58	34,939	55,127	181,736	Feb 18 08:47 PM
Andersen Jill	Chief Legal Officer, Secretary	Feb 17 '26	Sale	1.54	32,771	50,454	216,675	Feb 18 08:47 PM
Green Julie	Officer	Feb 17 '26	Proposed Sale	1.56	39,600	61,776		Feb 17 06:39 PM
Allen Robert D. III	Officer	Feb 17 '26	Proposed Sale	1.56	36,630	57,143		Feb 17 06:36 PM
Lee Timothy Edward	Officer	Feb 17 '26	Proposed Sale	1.56	39,600	61,776		Feb 17 06:32 PM
Duke William E.	Officer	Feb 17 '26	Proposed Sale	1.56	39,600	61,776		Feb 17 06:30 PM
Andersen Jill	Officer	Feb 17 '26	Proposed Sale	1.56	66,000	102,960		Feb 17 06:26 PM
ADIMAB, LLC	10% Owner	Dec 23 '25	Proposed Sale	3.00	192,320	577,498		Dec 23 04:23 PM
MCLAUGHLIN KEVIN F	Director	Nov 19 '25	Buy	2.50	50,000	125,000	50,000	Nov 20 04:22 PM
ADIMAB, LLC	10% Owner	Nov 17 '25	Proposed Sale	3.00	1,233,416	3,703,455		Nov 17 04:36 PM
Lee Timothy Edward	Chief Commercial Officer	Aug 19 '25	Sale	0.57	29,643	16,796	59,344	Aug 19 09:28 PM
Lee Timothy Edward	Chief Commercial Officer	Aug 18 '25	Sale	0.65	20,013	13,012	88,987	Aug 19 09:28 PM
Duke William E.	Chief Financial Officer	Aug 19 '25	Sale	0.57	29,643	16,796	49,344	Aug 19 09:25 PM
Duke William E.	Chief Financial Officer	Aug 18 '25	Sale	0.65	20,013	13,012	78,987	Aug 19 09:25 PM
Green Julie	Chief Human Resources Officer	Aug 19 '25	Sale	0.57	29,643	16,796	49,344	Aug 19 09:24 PM
Green Julie	Chief Human Resources Officer	Aug 18 '25	Sale	0.65	20,013	13,012	78,987	Aug 19 09:24 PM
Andersen Jill	Chief Legal Officer, Secretary	Aug 19 '25	Sale	0.57	49,402	27,991	84,446	Aug 19 09:21 PM
Andersen Jill	Chief Legal Officer, Secretary	Aug 18 '25	Sale	0.65	33,352	21,685	133,848	Aug 19 09:21 PM
Allen Robert D. III	Chief Scientific Officer	Aug 19 '25	Sale	0.57	27,420	15,536	53,068	Aug 19 09:20 PM
Allen Robert D. III	Chief Scientific Officer	Aug 18 '25	Sale	0.65	18,512	12,037	80,488	Aug 19 09:20 PM
Green Julie	Officer	Aug 18 '25	Proposed Sale	0.71	39,600	28,001		Aug 18 06:55 PM
Andersen Jill	Officer	Aug 18 '25	Proposed Sale	0.71	66,000	46,669		Aug 18 06:54 PM
Allen Robert D. III	Officer	Aug 18 '25	Proposed Sale	0.71	36,631	25,902		Aug 18 06:53 PM
Lee Timothy Edward	Officer	Aug 18 '25	Proposed Sale	0.71	39,600	28,001		Aug 18 06:49 PM
Duke William E.	Officer	Aug 18 '25	Proposed Sale	0.71	39,601	28,002		Aug 18 06:44 PM

Open in Screener

VCEL

Vericel Corp

May 15 • 11:09AM ET

33.17

+0.03 0.09 %

Healthcare • Biotechnology • USA • Small • NASD

Peers: ORGO MDXG BLFS IART ANIK

| Held by: IJR VTI XBI IWM VXF SPSM IJT IWO IBB SLYG

Index	RUT	P/E	81.10	EPS (ttm)	0.41	Insider Own	1.27%	Shs Outstand	51.01M	Perf Week	-0.87%
Market Cap	1.69B	Forward P/E	37.84	EPS next Y	0.88	Insider Trans	-12.62%	Shs Float	50.42M	Perf Month	-1.78%
Enterprise Value	1.64B	PEG	0.61	EPS next Q	-0.02	Inst Own	112.18%	Short Float	9.87%	Perf Quarter	-7.76%
Income	21.46M	P/S	5.80	EPS this Y	47.54%	Inst Trans	-1.12%	Short Ratio	7.63	Perf Half Y	-17.98%
Sales	292.09M	P/B	4.75	EPS next Y	85.65%	ROA	4.72%	Short Interest	4.98M	Perf YTD	-7.89%
Book/sh	6.98	P/C	11.65	EPS next 5Y	62.51%	ROE	6.59%	52W High	45.97 -27.85%	Perf Year	-20.05%
Cash/sh	2.85	P/FCF	35.67	EPS past 3/5Y	- 39.20%	ROIC	4.89%	52W Low	28.95 14.58%	Perf 3Y	-1.72%
Dividend Est.	-	EV/EBITDA	58.96	Sales past 3/5Y	18.90% 17.34%	Gross Margin	74.84%	Volatility	5.30% 5.69%	Perf 5Y	-34.67%
Dividend TTM	-	EV/Sales	5.63	EPS Y/Y TTM	602.15%	Oper. Margin	5.40%	ATR (14)	1.85	Perf 10Y	1032.07%
Dividend Ex-Date	-	Quick Ratio	4.79	Sales Y/Y TTM	22.45%	Profit Margin	7.35%	RSI (14)	44.40	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	5.18	EPS Q/Q	44.94%	SMA20	-4.39%	Beta	1.13	Target Price	55.43
Payout	0.00%	Debt/Eq	0.27	Sales Q/Q	30.09%	SMA50	-1.49%	Rel Volume	0.39	Prev Close	33.14
Employees	398	LT Debt/Eq	0.23	Earnings	May 07 BMO	SMA200	-6.45%	Avg Volume	651.94K	Price	33.17
IPO	Feb 04, 1997	Option/Short	Yes / Yes	EPS/Sales Surpr.	21.52% 7.46%	Trades		Volume	74,214	Change	0.09%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-17-25	Downgrade	BTIG Research	Buy → Neutral
Aug-09-24	Initiated	Canaccord Genuity	Buy	$57
Jun-20-24	Initiated	TD Cowen	Buy	$55
Jan-25-24	Upgrade	Truist	Hold → Buy	$39 → $51
Aug-08-23	Upgrade	BTIG Research	Neutral → Buy	$39
Nov-10-22	Downgrade	BTIG Research	Buy → Neutral
Nov-09-22	Downgrade	Truist	Buy → Hold
Oct-14-22	Resumed	Stephens	Overweight	$40
Jan-11-21	Downgrade	Oppenheimer	Outperform → Perform
Dec-18-20	Initiated	Stephens	Overweight	$31
Sep-17-20	Initiated	Truist	Buy	$24
Oct-09-19	Initiated	H.C. Wainwright	Buy	$19
Feb-28-19	Downgrade	Needham	Buy → Hold
Aug-08-18	Reiterated	Needham	Buy	$15 → $14
Jul-16-18	Upgrade	Ladenburg Thalmann	Neutral → Buy
Apr-04-18	Initiated	Leerink Partners	Outperform	$15
Mar-06-18	Reiterated	Needham	Buy	$5 → $15
Mar-06-18	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-05-18	Reiterated	BTIG Research	Buy	$8 → $13
Jun-21-17	Initiated	BTIG Research	Buy	$6

Show Previous Ratings

May-07-26 07:45AM	Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance (GlobeNewswire)
Apr-23-26 08:30AM	Vericel to Report First-Quarter 2026 Financial Results on May 7, 2026 (GlobeNewswire)
Apr-02-26 02:40PM	Vericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBrid (GlobeNewswire)
Mar-09-26 08:31PM	Vericel Corporation (VCEL) Secures FDA Approval for Commercial Manufacturing of MACI (Insider Monkey)
Mar-04-26 08:00AM	Vericel Announces FDA Approval of New State-of-the-Art Advanced Therapy Manufacturing Facility (GlobeNewswire)
08:30AM	Loading…
Mar-03-26 08:30AM	Vericel to Present at Multiple Upcoming Investor Conferences (GlobeNewswire)
Feb-28-26 08:05PM	MediWound Updates NexoBrid Growth, EscharEx Phase III Timeline and BARDA Talks at Oppenheimer Conference (MarketBeat)
Feb-27-26 12:39PM	Vericel Q4 Earnings Call Highlights (MarketBeat) -5.31%
Feb-26-26 08:09PM	Vericel Corporation Q4 2025 Earnings Call Summary (Moby)
04:11PM	Vericel Corp (VCEL) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ... (GuruFocus.com)
12:15PM	Vericel Corporation (VCEL) Matches Q4 Earnings Estimates (Zacks)
07:55AM	Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results (GlobeNewswire)
Feb-12-26 08:30AM	Vericel to Report Fourth-Quarter and Full-Year 2025 Financial Results on February 26, 2026 (GlobeNewswire)
Jan-13-26 12:57PM	Why Is Vericel Stock Gaining Tuesday? (Benzinga)
09:00AM	Vericel Announces Preliminary 2025 Financial Results and Business Updates (GlobeNewswire)
08:30AM	Loading…
Jan-06-26 08:30AM	Vericel to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 (GlobeNewswire) +6.09%
Dec-21-25 09:57AM	Truist Slashes PT on Vericel Corporation (VCEL) to $45 From $50 (Insider Monkey)
Nov-14-25 08:30AM	Vericel to Present at the Stephens Annual Investment Conference on Thursday, November 20, 2025 (GlobeNewswire)
Nov-10-25 09:55AM	Wall Street Analysts Believe Vericel (VCEL) Could Rally 39.42%: Here's is How to Trade (Zacks)
Nov-06-25 04:01PM	Vericel Corp (VCEL) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ... (GuruFocus.com)
09:10AM	Vericel Corporation (VCEL) Q3 Earnings and Revenues Top Estimates (Zacks)
07:55AM	Vericel Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-31-25 09:15AM	Emergent Biosolutions Inc. (EBS) Soars to 52-Week High, Time to Cash Out? (Zacks)
Oct-23-25 08:30AM	Vericel to Report Third-Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
Oct-22-25 08:48AM	Here's Why Vericel Corporation (VCEL) Underperformed in Q3 (Insider Monkey)
Oct-20-25 11:08PM	Truist Lowers PT on Vericel Corporation (VCEL) to $41 From $46 (Insider Monkey)
Sep-12-25 08:53AM	Here's Why Vericel Corp. (VCEL) Traded Down in Q2 (Insider Monkey)
Sep-11-25 03:46PM	Is the Options Market Predicting a Spike in Vericel Stock? (Zacks) +7.09%
Aug-28-25 08:30AM	Vericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025 (GlobeNewswire)
Aug-20-25 12:13AM	Leerink Partners Raises the PT Vericel (VCEL), Maintains a Buy Rating (Insider Monkey)
09:15AM	Loading…
Jul-31-25 09:15AM	Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -14.07%
08:08AM	Vericel Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-30-25 09:44AM	Earnings To Watch: Vericel Corp (VCEL) Reports Q2 2025 Result (GuruFocus.com)
09:00AM	Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Jul-24-25 09:47AM	Vericel Corporation (VCEL): A Bull Case Theory (Insider Monkey)
Jul-17-25 08:30AM	Vericel to Report Second-Quarter 2025 Financial Results on July 31, 2025 (GlobeNewswire)
Jun-10-25 08:30AM	Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025 (GlobeNewswire)
May-09-25 03:13AM	Vericel Corp (VCEL) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ... (GuruFocus.com)
May-08-25 09:05AM	Vericel Corporation (VCEL) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
08:45AM	Vericel Corporation (VCEL): Among Stocks with Insanely High PE Ratios Insiders Are Selling (Insider Monkey)
07:55AM	Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance (GlobeNewswire)
May-07-25 02:18PM	Vericel Q1 2025 Earnings Preview (Seeking Alpha) +5.25%
10:08AM	Earnings To Watch: Vericel Corp (VCEL) Reports Q1 2025 Result (GuruFocus.com)
08:30AM	Vericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025 (GlobeNewswire)
May-06-25 05:35PM	Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
May-01-25 05:15PM	Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-30-25 08:39AM	Vericel Corp. (VCEL) Faces Challenges as Burn Care Revenue Wanes and MACI Growth Remains Uncertain (Insider Monkey)
Apr-24-25 08:30AM	Vericel to Report First-Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
Mar-04-25 08:30AM	Vericel to Present at Multiple Upcoming Investor Conferences (GlobeNewswire)
Feb-28-25 02:11AM	Vericel Corp (VCEL) Q4 2024 Earnings Call Highlights: Record Revenue and Strong Growth Trajectory (GuruFocus.com)
01:51AM	Q4 2024 Vericel Corp Earnings Call (Thomson Reuters StreetEvents)
Feb-27-25 09:05AM	Vericel Corporation (VCEL) Tops Q4 Earnings Estimates (Zacks) -6.11%
07:54AM	Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results (GlobeNewswire)
Feb-26-25 07:28AM	Earnings To Watch: Vericel Corp (VCEL) Reports Q4 2024 Result (GuruFocus.com)
Feb-13-25 08:30AM	Vericel to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 27, 2025 (GlobeNewswire)
Jan-14-25 04:05PM	Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets (GlobeNewswire)
Jan-08-25 08:30AM	Vericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 (GlobeNewswire)
Dec-19-24 07:36AM	Vericel price target raised to $67 from $61 at Truist (TipRanks)
Nov-11-24 02:06PM	Vericel Stock Sees RS Rating Shoot Higher (Investor's Business Daily) +5.15%
Nov-08-24 04:03AM	Vericel Corp (VCEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic FDA ... (GuruFocus.com) +7.94%
Nov-07-24 09:10AM	Vericel Corporation (VCEL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:55AM	Vericel Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-06-24 07:15AM	Vericel Corp (VCEL) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com) +7.35%
Oct-24-24 08:30AM	Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024 (GlobeNewswire)
Oct-22-24 09:31AM	Vericel Corp. (VCEL) Cooled Down in Q3 After a 20% Rise in the First Half (Insider Monkey)
Oct-18-24 03:04PM	State Street Corp's Strategic Reduction in Vericel Corp Holdings (GuruFocus.com)
Oct-09-24 03:44PM	Vericel Corp (VCEL) Q2 2024 Earnings Call Highlights: Record Revenue and Strategic Growth ... (GuruFocus.com)
Aug-29-24 09:17AM	Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024 (GlobeNewswire)
Aug-26-24 07:45AM	Vericel Announces FDA Approval and Commercial Availability of MACI Arthro (GlobeNewswire)
Aug-16-24 10:33AM	MediWound and Vericel win FDA paediatric label expansion for NexoBrid (Medical Device Network)
Aug-15-24 04:05PM	Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns (GlobeNewswire)
Aug-07-24 08:30AM	Vericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024 (GlobeNewswire)
Aug-05-24 12:00PM	What Makes Vericel (VCEL) a New Strong Buy Stock (Zacks)
Aug-01-24 09:05AM	Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.94%
07:55AM	Vericel Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-29-24 03:45PM	AppFolio, Inc. (APPF): One of Ray Dalio's Top 10 Growth Stock Picks Right Now? (Insider Monkey)
Jul-22-24 08:30AM	Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer (GlobeNewswire)
Jul-18-24 08:30AM	Vericel to Report Second-Quarter 2024 Financial Results on August 1, 2024 (GlobeNewswire)
Jul-16-24 07:01PM	Insider Sale: CFO Mara Joseph Anthony Jr Sells 5,000 Shares of Vericel Corp (VCEL) (GuruFocus.com)
Jul-02-24 09:58AM	Should You Consider Adding Vericel Corporation (VCEL) to Your Portfolio? (Insider Monkey)
Jun-27-24 02:03PM	The 3 Highest-Rated Medical Stocks You Can Buy Today (InvestorPlace)
Jun-25-24 07:22AM	Factors Behind Vericel Corporation (VCEL) Stock's Positive Momentum (Insider Monkey)
Jun-20-24 09:54AM	Spirit Aero downgraded, Skyworks upgraded: Wall Street's top analyst calls (The Fly)
Jun-11-24 08:30AM	Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024 (GlobeNewswire)
May-22-24 08:30AM	Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024 (GlobeNewswire)
May-21-24 06:42AM	Multiple Factors Pushed Vericel Corp. (VCEL) in Q1 (Insider Monkey)
May-09-24 03:28PM	Vericel Corporation (NASDAQ:VCEL) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:08AM	Vericel Corp (VCEL) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ... (GuruFocus.com)
May-08-24 11:24PM	Q1 2024 Vericel Corp Earnings Call (Thomson Reuters StreetEvents)
09:35AM	Vericel Corp (VCEL) Surpasses Q1 Revenue Forecasts with Strong Growth in Core Markets (GuruFocus.com)
09:10AM	Vericel Q1 Loss Narrows, Revenue Increases; 2024 Outlook Lifted -- Shares Rise Pre-Bell (MT Newswires)
07:55AM	Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance (GlobeNewswire)
Apr-24-24 08:30AM	Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024 (GlobeNewswire)
Mar-29-24 07:01PM	Director ZERBE ROBERT L MD Sells Shares of Vericel Corp (VCEL) (GuruFocus.com)
Mar-28-24 01:48PM	Land Developer And A Specialty Medical Stock Burst Into Buy Zones (Investor's Business Daily)
Mar-15-24 07:00PM	Vericel Corp President and CEO Dominick Colangelo Sells 35,000 Shares (GuruFocus.com)
Mar-01-24 09:30AM	Vericel Corporation (NASDAQ:VCEL) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 11:37PM	Q4 2023 Vericel Corp Earnings Call (Thomson Reuters StreetEvents)
09:05AM	Vericel Corporation (VCEL) Q4 Earnings Beat Estimates (Zacks)
08:32AM	Vericel Corp (VCEL) Reports Robust Revenue and EBITDA Growth in Q4 and Full-Year 2023 (GuruFocus.com)

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wotton Paul K	Director	May 11 '26	Sale	32.74	10,000	327,425	18,802	May 13 04:05 PM
MCLAUGHLIN KEVIN F	Director	May 13 '26	Proposed Sale	32.57	7,000	227,990		May 13 02:16 PM
Wotton Paul K	Director	May 11 '26	Proposed Sale	32.74	10,000	327,425		May 11 02:32 PM
Mara Joseph Anthony Jr	Chief Financial Officer	May 07 '26	Sale	40.50	5,000	202,500	21,009	May 08 04:05 PM
SIEGAL JONATHAN	Principal Accounting Officer	May 06 '26	Sale	38.00	3,433	130,454	2,540	May 08 04:05 PM
SIEGAL JONATHAN	Principal Accounting Officer	May 07 '26	Sale	40.50	1,422	57,591	1,118	May 08 04:05 PM
SIEGAL JONATHAN	Officer	May 07 '26	Proposed Sale	40.50	1,422	57,591		May 07 12:36 PM
Mara Joseph Anthony Jr	Officer	May 07 '26	Proposed Sale	40.50	5,000	202,500		May 07 12:02 PM
SIEGAL JONATHAN	Officer	May 06 '26	Proposed Sale	38.00	3,433	130,454		May 06 03:30 PM
Hopper Jonathan Mark	Chief Medical Officer	Apr 02 '26	Option Exercise	10.95	3,472	38,018	79,028	Apr 06 04:05 PM
Hopper Jonathan Mark	Chief Medical Officer	Apr 02 '26	Sale	35.00	3,472	121,520	75,556	Apr 06 04:05 PM
Hopper Jonathan Mark	Officer	Apr 02 '26	Proposed Sale	35.00	3,472	121,520		Apr 02 02:28 PM
Rubino Alan L	Director	Mar 25 '26	Option Exercise	2.76	15,000	41,400	60,994	Mar 27 04:05 PM
Hagen Heidi	Director	Mar 23 '26	Option Exercise	2.76	15,000	41,400	46,850	Mar 25 04:05 PM
Hagen Heidi	Director	Mar 23 '26	Sale	32.41	15,000	486,150	31,850	Mar 25 04:05 PM
Hagen Heidi	Director	Mar 23 '26	Proposed Sale	32.41	15,000	486,163		Mar 23 04:08 PM
Flynn Sean C.	Chief Legal Officer	Mar 02 '26	Option Exercise	16.25	15,000	243,750	16,262	Mar 04 04:05 PM
Flynn Sean C.	Chief Legal Officer	Mar 02 '26	Sale	35.18	21,421	753,530	1,262	Mar 04 04:05 PM
Halpin Michael	Chief Operating Officer	Mar 02 '26	Sale	35.30	10,305	363,766	16,080	Mar 04 04:05 PM
Flynn Sean C.	Officer	Mar 02 '26	Proposed Sale	35.18	21,421	753,509		Mar 02 04:54 PM
Halpin Michael	Officer	Mar 02 '26	Proposed Sale	35.30	10,305	363,749		Mar 02 04:21 PM
Colangelo Dominick	President and CEO	Feb 24 '26	Option Exercise	0.00	18,250	0	321,270	Feb 26 04:05 PM
Hopper Jonathan Mark	Chief Medical Officer	Feb 24 '26	Option Exercise	0.00	4,650	0	76,192	Feb 26 04:05 PM
SIEGAL JONATHAN	Principal Accounting Officer	Feb 24 '26	Option Exercise	0.00	3,415	0	6,585	Feb 26 04:05 PM
Mara Joseph Anthony Jr	Chief Financial Officer	Feb 24 '26	Option Exercise	0.00	9,250	0	27,262	Feb 26 04:05 PM
Halpin Michael	Chief Operating Officer	Feb 24 '26	Option Exercise	0.00	10,500	0	28,871	Feb 26 04:05 PM
Flynn Sean C.	Chief Legal Officer	Feb 24 '26	Option Exercise	0.00	6,500	0	9,014	Feb 26 04:05 PM
Colangelo Dominick	President and CEO	Feb 18 '26	Option Exercise	0.00	11,700	0	290,427	Feb 20 04:06 PM
Flynn Sean C.	Chief Legal Officer	Feb 18 '26	Option Exercise	0.00	5,325	0	5,097	Feb 20 04:06 PM
Hopper Jonathan Mark	Chief Medical Officer	Feb 18 '26	Option Exercise	0.00	2,325	0	72,009	Feb 20 04:06 PM
Mara Joseph Anthony Jr	Chief Financial Officer	Feb 18 '26	Option Exercise	0.00	7,380	0	20,179	Feb 20 04:06 PM
SIEGAL JONATHAN	Principal Accounting Officer	Feb 18 '26	Option Exercise	0.00	2,920	0	4,682	Feb 20 04:06 PM
Halpin Michael	Chief Operating Officer	Feb 18 '26	Option Exercise	0.00	9,075	0	22,669	Feb 20 04:06 PM
MCLAUGHLIN KEVIN F	Director	Feb 11 '26	Option Exercise	2.63	7,000	18,410	22,100	Feb 13 04:05 PM
MCLAUGHLIN KEVIN F	Director	Feb 11 '26	Sale	34.66	7,000	242,620	15,100	Feb 13 04:05 PM
MCLAUGHLIN KEVIN F	Director	Feb 11 '26	Proposed Sale	35.62	7,000	249,340		Feb 11 10:07 AM
Halpin Michael	Chief Operating Officer	Jan 07 '26	Option Exercise	16.66	10,000	166,600	26,080	Jan 09 04:05 PM
Halpin Michael	Chief Operating Officer	Jan 07 '26	Sale	40.48	10,000	404,800	16,080	Jan 09 04:05 PM
Halpin Michael	Officer	Jan 07 '26	Proposed Sale	40.48	10,000	404,833		Jan 07 04:22 PM
Mahoney Karen	Chief Human Resources Officer	Jul 22 '25	Option Exercise	0.00	2,625	0	2,625	Dec 12 04:05 PM
Hopper Jonathan Mark	Chief Medical Officer	Dec 02 '25	Option Exercise	18.00	1,652	29,736	68,214	Dec 04 04:05 PM
Hopper Jonathan Mark	Chief Medical Officer	Dec 02 '25	Sale	39.14	1,652	64,659	66,562	Dec 04 04:05 PM
Wotton Paul K	Director	Dec 02 '25	Sale	37.97	2,500	94,925	28,102	Dec 04 04:05 PM
Wotton Paul K	Director	Dec 03 '25	Sale	37.83	2,500	94,575	25,602	Dec 04 04:05 PM
Wotton Paul K	Director	Dec 03 '25	Proposed Sale	37.83	2,500	94,575		Dec 03 11:25 AM
Wotton Paul K	Director	Dec 02 '25	Proposed Sale	37.97	2,500	94,919		Dec 02 04:08 PM
Hopper Jonathan Mark	Officer	Dec 02 '25	Proposed Sale	39.14	1,652	64,659		Dec 02 10:10 AM
Halpin Michael	Chief Operating Officer	Nov 11 '25	Option Exercise	16.66	2,642	44,016	18,574	Nov 13 04:05 PM
Halpin Michael	Chief Operating Officer	Nov 11 '25	Sale	40.41	2,642	106,763	15,932	Nov 13 04:05 PM
MCLAUGHLIN KEVIN F	Director	Nov 10 '25	Option Exercise	2.63	7,000	18,410	22,100	Nov 12 04:06 PM
MCLAUGHLIN KEVIN F	Director	Nov 10 '25	Sale	38.59	7,000	270,130	15,100	Nov 12 04:06 PM
Halpin Michael	Officer	Nov 11 '25	Proposed Sale	40.41	2,642	106,760		Nov 12 07:33 AM
Halpin Michael	Chief Operating Officer	Nov 06 '25	Option Exercise	16.66	7,358	122,584	23,290	Nov 10 04:05 PM
Halpin Michael	Chief Operating Officer	Nov 06 '25	Sale	40.47	7,358	297,778	15,932	Nov 10 04:05 PM
MCLAUGHLIN KEVIN F	Director	Nov 10 '25	Proposed Sale	39.71	7,000	277,970		Nov 10 02:47 PM
Halpin Michael	Officer	Nov 06 '25	Proposed Sale	40.47	7,358	297,775		Nov 06 04:19 PM
SIEGAL JONATHAN	Principal Accounting Officer	Sep 30 '25	Option Exercise	0.00	938	0	2,440	Oct 02 04:05 PM
Hopper Jonathan Mark	Chief Medical Officer	Sep 02 '25	Option Exercise	18.00	10,000	180,000	76,363	Sep 03 04:06 PM
Hopper Jonathan Mark	Chief Medical Officer	Sep 02 '25	Sale	35.77	10,000	357,700	66,363	Sep 03 04:06 PM
Hopper Jonathan Mark	Officer	Sep 02 '25	Proposed Sale	35.77	10,000	357,700		Sep 02 12:14 PM
MCLAUGHLIN KEVIN F	Director	Aug 06 '25	Option Exercise	2.76	7,000	19,320	22,100	Aug 08 04:05 PM
MCLAUGHLIN KEVIN F	Director	Aug 06 '25	Sale	35.92	7,000	251,440	15,100	Aug 08 04:05 PM
MCLAUGHLIN KEVIN F	Director	Aug 06 '25	Proposed Sale	35.92	7,000	251,457		Aug 06 05:18 PM
Hopper Jonathan Mark	Chief Medical Officer	Jun 02 '25	Option Exercise	18.00	10,000	180,000	76,237	Jun 04 04:05 PM
Hopper Jonathan Mark	Chief Medical Officer	Jun 02 '25	Sale	40.09	10,000	400,900	66,237	Jun 04 04:05 PM
Hopper Jonathan Mark	Officer	Jun 02 '25	Proposed Sale	41.13	10,000	411,300		Jun 02 10:50 AM
GILMAN STEVEN C	Former Director	May 30 '25	Proposed Sale	42.00	13,125	551,250		May 30 03:58 PM

IVVD

Invivyd Inc

VCEL

Vericel Corp

Upgrade your Finviz experience